Find Clinical Trials

Inclusion Criteria: * Participants must be ≥ 18 years of age. * Participants must have histologically confirmed diagnosis of a locally advanced, unresectable, or metastatic solid tumor malignancy. * Participants must have a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 * Participants must have a stable Eastern Cooperative Oncology Group Performance Status of 0 or 1. * For Part 2A only, participants must have CCNE1-amplified ovarian cancer Exclusion Criteria: * Participants must not have an active brain metastasis. * Participants must not have impaired cardiac function or clinically significant cardiac disease. * Participants must not have bleeding disorder or any history of clinically significant bleeding within the prior 3 months. * Participants must not have Grade ≥ 2 peripheral neuropathy. * Other protocol-defined Inclusion/Exclusion criteria apply.

Inclusion Criteria: * identify as a primary caregiver of any gender to an 18- to 107-month-old child * reside in Canada with access to internet connection * be aged 18 years or older * able to understand/read/speak in English * report at least mild emotional distress across depression, anxiety, anger, or parenting stress symptoms as assessed by the PHQ-9, GAD-7, PROMIS-Anger, and PSI * have access to an electronic device Exclusion Criteria: * below the age of 18 years * parenting a child outside the designated age range * live outside Canada * have participated in previous iterations of BEAM

Inclusion Criteria: * Patients with BI-RADS 4 lesion. Exclusion Criteria: * Patients on chemotherapy or related treatment. * Patients who have contraindications to do MRI as patients with cardiac pace maker, patients with cochlear implant and ocular foreign body, claustrophobia.

Inclusion Criteria: * Patients are females. * Patient with post mastectomy unilateral lymphedema. * Their age will range from (30-50) years. * Patients will be given their informed consent. Exclusion Criteria: * Musculoskeletal disorders that will impair performance during training and tests. * Uncontrolled cardiovascular or pulmonary diseases. * Neurological and renal disorders. * Metabolic or vascular disease with a neurological component such as diabetes. * Malignant conditions. * Primary lymphedema. * Psychiatric illness, severe behavior or cognitive disorders. * Uncooperative patients. * Pregnancy.

Inclusion Criteria: * Only female patients underwent reconstruction mammoplasty will participate in the study. * Female patients who stopped chemotherapy at least one month before participation in the study. * Female patients with chronic pain following cosmetic breast surgery. * All patients who will accept to participate in the study after one week from operation. Exclusion Criteria: * Patients have irritable bowel syndrome. * Patients have urinary incontinence. * Chronic diseases like multiple sclerosis, polyneuropathy , diabetes and fibromyalgia. * Patients have cognitive disorder. * Patients with chronic and severe back pain. * Sepsis with complications postoperative hemodynamics. * Patients take anti-psychotic drugs. * Patients take hypnotic drugs.

Inclusion Criteria: * 18-65 years old (inclusive) * Fluent and literate in English, with non-impaired intellectual abilities to ensure adequate comprehension of the task instructions. * Willing to provide written, informed consent. * Functional magnetic resonance imaging (fMRI) scanning eligibility. All participants will need to successfully complete the screening forms at the Stanford Center for Cognitive and Neurobiological Imaging (CNI). * Patient Health Questionnaire-8 (PHQ-8) \>/= 10 * Meet the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) diagnostic criteria for current or recurrent nonpsychotic Major Depressive Disorder (MDD) established by the Mini International Neuropsychiatric Interview (MINI) Exclusion Criteria: * Suicidality with active plan or as determined clinician judgment * Current or lifetime history of medical illness or brain injury that may interfere with assessments as determined by clinician judgment * Severe impediment to vision, hearing, and/or hand movement likely to interfere with ability to complete the assessments, or is unable and/or unlikely to follow the study protocols as determined by clinician judgment * Pregnant, breastfeeding or unwilling or unable to use adequate birth control throughout the study * History of non-responsive depression to dopamine agonists * Any contraindication to being scanned in the 3.0T fMRI scanner, such as a cardiac pacemaker or implanted device that has not been cleared for scanning * Previous or current DSM-5 bipolar disorder (I, II, not otherwise specified), schizophrenia spectrum or other psychotic disorders, or psychosis or as determined by clinician judgment * Previous or current diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) * Meeting DSM-5 criteria for current Obsessive-Compulsive Disorder (OCD) or eating disorder * Meeting DSM-5 criteria for alcohol use disorder or substance use disorder within the last 12 months * Clinically significant presence/history of impulsive-compulsive behaviors or control disorder including but not limited to gambling disorder within the last 12 months. * Current use or use of psychotropic medication within the past month. (If the participant's usual treating clinician agrees with discontinuing the medication, participants may enroll after tapering off the medication under the supervision of either their usual clinician or the study clinician. A washout period of 5 half-lives-or a different duration as determined by the study clinician-must be completed before the first scan.) * Concurrent participation in other intervention or treatment studies

Inclusion Criteria: * ASA Ⅰ\~Ⅲ; * BMI was 18-28 kg/m2; * For elective abdominal surgery under intravenous general anesthesia; * The expected duration of anesthesia was 1 to 4 hours. Exclusion Criteria: * Septic shock and multiple organ failure diagnosed within 14 days; * Hyperkalemia (serum potassium \>5.5mmol/L) within 48 hours; * Stroke or transient ischemic attack within 3 months; * Patients with unstable angina pectoris or myocardial infarction within 3 months; Arrhythmia requiring treatment was not treated or treatment did not meet expectations; * Patients with preoperative diagnosed diabetes mellitus and uncontrolled blood glucose; Diabetic complications were diagnosed before surgery, including diabetic ketoacidosis, hyperosmolar coma, diabetes-related infection, diabetic nephropathy, retinopathy, diabetic cardiomyopathy, diabetic neuropathy, diabetic foot, etc. * Severe liver and renal dysfunction; * Liver surgery, renal surgery, adrenal surgery, day surgery; * Resting blood pressure ≥180/110 mmHg (2020 ISH hypertension guideline ≥ grade 3 hypertension); Or systolic blood pressure \<90mmHg or mean blood pressure \<65mmHg. * Taking corticosteroids or other immunosuppressants for more than 10 days within 6 months or having a history of adrenal cortex suppression or immune system diseases;

Inclusion Criteria: -1. Age: Female patients aged ≥65 years. 2. Disease Status: Histologically confirmed early-stage breast cancer after surgery with ER expression ≥50% AND one of the following: 1. ≥4 positive lymph nodes 2. 1-3 positive lymph nodes plus at least one of the following high-risk features: i. High-risk multigene assay result ii. Primary tumor size \>2 cm iii. Histologic grade 3 iv. Lymphovascular invasion (LVI) positive v. Ki-67 \>20% 3. Treatment Acceptance: Willing to receive adjuvant CDK4/6 inhibitor therapy. 4. Performance Status: ECOG score 0-2. 5. Adequate Organ Function: a) Hematology (within 14 days, no transfusion): i. Hemoglobin (Hb) ≥90 g/L ii. Absolute neutrophil count (ANC) ≥1.5×10⁹/L iii. Platelets (PLT) ≥100×10⁹/L b) Biochemistry: i. Total bilirubin (TBIL) ≤1.5×ULN ii. ALT/AST ≤3×ULN iii. Serum creatinine (Cr) ≤1×ULN iv. Estimated creatinine clearance (CrCl) \>50 mL/min (Cockcroft-Gault formula) 6. Consent \& Compliance: Willing to participate, sign informed consent, and comply with follow-up. Exclusion Criteria: * 1\. Patients who have received neoadjuvant therapy (including chemotherapy, targeted therapy, radiotherapy, or endocrine therapy). 2\. Bilateral breast cancer. 3. History of other malignancies, except: Cured basal cell carcinoma of the skin； Carcinoma in situ of the cervix 4. Distant metastasis (any site). 5. Any T4 lesion (UICC 1987 TNM staging), including: Skin invasion; Fixed mass adherence; Inflammatory breast cancer 6. Concurrent participation in other clinical trials. 7. Severe organ dysfunction (cardiac, pulmonary, hepatic, or renal), including: a) LVEF \<50% (by echocardiography) b) Major cardiovascular/cerebrovascular events within 6 months before randomization: i. Unstable angina ii. Chronic heart failure iii. Uncontrolled hypertension (\>150/90 mmHg) iv. Myocardial infarction or stroke c) Poorly controlled diabetes mellitus d) Severe hypertension 8. Known allergy to taxane-based drugs or their excipients. 9. Severe or uncontrolled infections. 10. History of psychoactive drug abuse (unable to abstain) or psychiatric disorders. 11\. Patients deemed ineligible by investigator assessment. 12. Refusal to receive adjuvant CDK4/6 inhibitor therapy.

Inclusion criteria: 1. Adult patients with asthma are 25 - 64 years of age. 2. Have been receiving medications from the pharmacy of either Inhaled Corticosteroids (ICS) or a fixed combination of ICS with a long-acting beta-agonist (bronchodilator) and regular patronage of the pharmacy for the previous six months. 3. Confirmed diagnosis from either the physician's diagnosis or the patient's self-report. 4. No respiratory comorbidities (i.e., COPD or lung diseases). 5. Uses a smartphone (IOS or Android). 6. Ability to communicate with the pharmacist in English. 7. Volunteer to participate in the program for the period. Exclusion criteria: 1. The adult patient with asthma aged \< 25 years or \> 64 years old. 2. The patient with one of the following - coronary heart disease, severe hypertension, severe heart failure, severe musculoskeletal disorder, mental health condition, dementia, chronic obstructive lung disease, or COVID-19. 3. Participating in another "Pharmacy Counseling or Education Program." 4. The patient does not have a smartphone (iOS or Android). 5. The patient does not have sufficient comprehension or the ability to communicate effectively in English. 6. The patient is unwilling or unable to participate in the entire program.

Inclusion Criteria: 1. Physical Disability 2. Diagnosed with Type 2 Diabetes 3. Hemoglobin A1c ≥7% within 3 months of screening 4. Must have at least 1 additional chronic conditions from the list below Hypertension Congestive Heart Failure Coronary Artery Disease Hyperlipidemia Stroke Arthritis Asthma Cancer Chronic Kidney Disease (Stages 1-4) COPD Osteoporosis Multiple Sclerosis Parkinsons Exclusion Criteria: 1. Intellectual, Learning, Developmental Disabilities 2. Non-english speakers 3. Currently pregnant 4. Significant vision loss preventing use of phone/tablet for interventions 5. Received Remote Patient Monitoring or Digital Health Coaching for T2DM management within 30 days of enrollment 6. End-stage kidney disease (on dialysis) 7. Does not report having a physical disability 8. Perceived unwillingness or inability to participate

Inclusion Criteria: 1. Age ≥ 18 years, gender unrestricted; 2. Clinically diagnosed with type 2 diabetes; 3. First-time treatment with metformin and empagliflozin tablets; 4. HbA1c test results within 2 weeks prior to enrollment (rapid fingertip test results are acceptable); 5. Voluntary participation in the study and signing of informed consent form. Exclusion Criteria: 1. Moderate to severe renal impairment (eGFR \< 45 mL/min/1.73 m²), end-stage renal disease, or dialysis; 2. Acute or chronic metabolic acidosis, including diabetic ketoacidosis; 3. A history of severe allergy to empagliflozin, metformin, or any excipient in this product; 4. Currently or within the past month, participation in any other clinical trials; 5. Judged by the investigator to be unsuitable for participation in this study.

Inclusion Criteria: * age 18-90 * health participants: without cancer over 5 years * cancer participants: diagnosis of breast cancer * cancer participants: agree to receive treatment in Chang Gung hospital Exclusion Criteria: * mental disease * Physician's assessment not suitable

Inclusion Criteria: * Women over 18 years old * Pregnant or having given birth less than a year ago * First psychiatric consultation for the pregnancy concerned. * Good command of the French language. * Participant affiliated to the social security system * Participant who has given her consent to take part in the study. Exclusion Criteria: * Women who gave birth more than a year ago. * Participant under psychiatric care * Participant under court protection

Inclusion Criteria: * Age ≥19 years * Diagnosed with PA per 2016 Endocrine Society guidelines * Underwent adrenal CT * Signed informed consent Exclusion Criteria: * Women who are pregnant, breastfeeding, or may become pregnant * Individuals who refuse to undergo surgery * Individuals for whom 68Ga-Pentixafor PET/CT, 11C-Metomidate PET/CT, or adrenal venous sampling (AVS) is not feasible or is refused due to underlying conditions * Individuals who refuse or experience adverse effects from dexamethasone premedication required for 11C-Metomidate PET/CT * Individuals with a history of abdominal open surgery or retroperitoneal surgery on the same side as the planned adrenalectomy * Any individual deemed unsuitable for the study at the discretion of the investigator

Inclusion Criteria: * Patients with Type 2 diabetes mellitus patients. * Patients were having fatty liver changes by fibro scan and with mild to moderate elevation of serum liver enzymes or without. * patients taking insulin or anti-diabetic medications. * Patients have Renal dysfunction. * Patients have Cardiac problem Exclusion Criteria: * Patients with a history of alcohol, smoking, uncontrolled diabetes. * Pregnancy. * Lactation. * Chronic liver and decompensated liver disease in hepatitis B and C. * patients whose abdominal ultrasounds findings were extremely abnormal (mass, fibrosis, ascites, and cirrhosis) and amino transaminase levels were severely high (ALT and AST greater than 15 times the upper limit of normal according to Johns Hopkins Diabetes Guide) suggest severe liver cell injury was also worked for acute viral hepatitis.

Inclusion Criteria: * Aged 18-28 * No history of physical or psychological illness * Able to provide informed consent * Voluntarily agreed to participate Exclusion Criteria: * History of chronic illness or psychiatric disorder * Communication difficulties

Inclusion Criteria: * Aged between 18 and 65 years, * Histologically confirmed diagnosis of Stage I-IIIA lung cancer according to the 9th edition of the AJCC Cancer Staging Manual, * Underwent lobectomy, pneumonectomy, segmentectomy, or wedge resection via video-assisted thoracoscopic surgery (VATS) or robot-assisted thoracoscopic surgery (RATS), * An estimated life expectancy of ≥6 months, * Karnofsky Performance Status score greater than 80% at study entry, * Possession of the necessary equipment and access to a stable internet connection to enable participation in online interventions. Exclusion Criteria: * History of receiving radiotherapy or chemotherapy prior to surgery, * Presence of severe dysfunction in vital organs such as the heart, brain, kidneys, or others, * Having any comorbid condition that contraindicates participation in an exercise training program, * Presence of serious postoperative complications, * Cognitive impairments that hinder effective communication, * Current participation in a structured and regular exercise program, * Missing three consecutive weeks of sessions or completing less than 75% of the prescribed exercises, * Voluntary withdrawal from the study by the participant.

Inclusion Criteria: 1. Informed Consent and Compliance The patient has fully understood this study and voluntarily signed the informed consent form, demonstrating the ability and willingness to comply with the study protocol-defined visits, treatment plans, laboratory tests, and other study procedures. 2. Age and Gender Female patients aged 18 to 70 years old (inclusive) on the day of signing the informed consent. 3. Prior Neoadjuvant Chemotherapy without pCR Received prior neoadjuvant chemotherapy containing anthracycline or taxane agents without achieving pathological complete response (pCR). Neoadjuvant chemotherapy requirement: At least 4 completed cycles. Non-pCR definition: Residual invasive carcinoma confirmed by pathology after primary tumor resection. 4. Surgical Resection Underwent complete surgical resection (R0) with pathologically confirmed negative margins. 5. Triple-Negative Breast Cancer Confirmation Post-resection tumor tissue confirmed as ER-negative, PR-negative, and HER2-negative breast cancer by immunohistochemistry (IHC): ER-negative: \<1% expression by IHC. PR-negative: \<1% expression by IHC. HER2-negative: IHC score of 0 or 1+, or 2+ with negative in situ hybridization (ISH) results. 6. Postoperative Treatment No prior systemic anticancer therapy (excluding radiotherapy) after breast cancer surgery. 7. Performance Status ECOG performance status of 0 to 1. 8. Hematological Criteria (within 1 week prior to enrollment) Blood tests meet the following criteria (CTCAE v5.0 ≤ Grade 1, based on institutional laboratory standards): White blood cell (WBC) count ≥ 3.0 × 10\^9/L. Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L. Platelet (PLT) count ≥ 100 × 10\^9/L. Hemoglobin ≥ 9.0 g/dL. No administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF), blood products, or erythropoietin (EPO) within 14 days prior to enrollment. 9. Biochemical Criteria (within 1 week prior to enrollment) Normal blood biochemistry (CTCAE v5.0 ≤ Grade 1, based on institutional laboratory standards): Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN). Alanine aminotransferase (ALT) ≤ 1.5 × ULN. Aspartate aminotransferase (AST) ≤ 1.5 × ULN. Alkaline phosphatase (ALP) ≤ 2.5 × ULN. Creatinine clearance (Ccr) ≥ 50 mL/min. Contraception Requirements Fertile patients must agree to use highly effective contraception (hormonal, barrier methods, or abstinence) with their partners during the trial and for at least 6 months after the last dose. Premenopausal female patients must have a negative blood or urine pregnancy test before enrollment. Exclusion Criteria: 1. Stage IV metastatic breast cancer. 2. Bilateral breast cancer. 3. History of other malignancies within the past 5 years, except for cured basal cell carcinoma of the skin, cervical carcinoma in situ, or papillary thyroid carcinoma. 4. Radiotherapy within 2 weeks prior to the first dose of the study drug. 5. Surgery within 2 weeks prior to the first dose of the study drug. 6. Prior treatment with utidelone or capecitabine, known hypersensitivity to utidelone, capecitabine, or fluoropyrimidines, or confirmed dihydropyrimidine dehydrogenase (DPD) deficiency. 7. Prior adverse reactions to anticancer therapy have not recovered to CTCAE v5.0 Grade ≤1 (excluding toxicities deemed non-risky by the investigator, such as alopecia). 8. Gastrointestinal disorders (e.g., esophageal obstruction, pyloric obstruction, intestinal obstruction), post-gastrointestinal resection, or other factors causing dysphagia that may interfere with oral drug absorption. 9. Severe comorbidities, including significant cardiac/cerebrovascular disease, uncontrolled diabetes/hypertension, active infections, or active peptic ulcer. 10. Active hepatitis B virus (HBV) infection. 11. History of immunodeficiency (e.g., HIV-positive status, congenital/acquired immunodeficiency disorders) or organ transplantation. 12. Psychiatric disorders or poor compliance. 13. Pregnancy (positive pregnancy test) or lactation. 14. Concurrent participation in another interventional clinical study or receiving other investigational therapies. 15. Concomitant use of potent CYP3A4 inhibitors/inducers or QT-prolonging drugs within 14 days prior to the first dose or during the study. 16. Other conditions deemed unsuitable for study participation by the investigator.

Key Inclusion Criteria: * Male or female aged ≥ 18 years old at screening with Eastern Cooperative Oncology Group (ECOG) 0-1 and life expectancy \> 3 months * Patients with histologically or cytologically proven advanced malignancies of preferred indications * Measurable disease (as assessed by investigator using RECIST v1.1) is preferred in Phase 1 dose escalation, unless otherwise specified in the protocol, and in all patients in Phase 2. Bone only disease is allowed in dose escalation. * Agree to provide molecular test report results to confirm eligibility and archival tumor samples and/or fresh biopsy, as applicable * Adequate renal, liver, and bone marrow function Key Exclusion Criteria: * Patients should not have received any prior selective investigational CDK (CDK2, CDK4, CDK2/4, CDK2/4/6) inhibitors * Has known active brain metastasis (have either previously untreated intracranial CNS metastasis or previously treated intracranial central nervous system (CNS) metastasis with radiologically documented new or progressing CNS lesions) or leptomeningeal disease * Other concurrent invasive malignancy or a prior invasive malignancy for which treatment was completed within 3 years before the first dose on study except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ, or colorectal adenomatous polyps * Last anticancer treatment within 2 weeks (4 weeks for biologic, immunotherapy or ADC) or 5 half-lives of the drug, whichever is shorter, prior to first dose on study * Major surgery within 4 weeks prior to first dose on study * Have received radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment, except for patients receiving whole brain radiotherapy, which must be completed at least 4 weeks prior to the first dose of study treatment. Patients must have recovered from all radiation-related toxicities, not require corticosteroids, and not have active radiation pneumonitis. Patients who received radiation of \>25% of bone marrow are excluded. * Strong or moderate CYP3A4 inhibitors or inducers within 2 weeks or 5 half-lives of the drug, whichever is shorter, prior to first dose on study * History of serious cardiovascular conditions within 6 months prior to first dose on study * Unresolved toxicities from prior therapy greater than Grade 1 (per CTCAE version 5.0) (with exceptions of alopecia, vitiligo, and ≤ Grade 2 peripheral neuropathy) prior to the first dose on study * History of drug-induced pneumonitis/interstitial lung disease * Confirmed loss of function mutation or deletion of Rb1 gene * Previous high-dose chemotherapy requiring stem cell rescue

Inclusion Criteria: * part-time or full-time employment (at least 20 hours per week); * ≥18 years old; * employed in low-wage-earning jobs in the Environmental Services or Food \& Nutrition Services Departments; * presence of depression symptoms as measured by the Patient Health Questionnaire-9 item version; individuals who score ≥5 (indicating mild depression symptoms or higher) will be eligible; * presence of impairment in work functioning, as measured by the Work Limitations Questionnaire; individuals who score ≥5% (indicating mild work productivity loss) will be eligible; * possession of a cell phone with ability to receive text-messages; * Fluent in either English or Spanish. Exclusion Criteria: * plan to leave Scripps employment in \<6 months; * severe mental illness or substance use condition (e.g., bipolar disorder, schizophrenia, active alcohol use disorder)